Pittsburgh to Test Weekly Semaglutide in 1,200-Adult Trial Targeting Addiction and Justice Involvement

PITTSBURGH — A sweeping new randomized controlled trial is set to test one of the most talked-about questions in modern addiction medicine: whether semaglutide, the blockbuster GLP-1 receptor agonist better known by the brand names Ozempic and Wegovy, can help people with alcohol and opioid use disorder reduce their substance use, rebuild their lives, and stay out of the criminal justice system. The Center for Addiction Science, Policy and Research (CASPR) and the Allegheny County Department of Human Services have announced plans for a $13.3 million study, funded through a grant from Arnold Ventures, that will enroll up to 1,200 adults across multiple sites beginning in early 2027. The trial represents one of the largest and most ambitious efforts to date to determine whether a medication already approved for type 2 diabetes and weight management can deliver measurable benefits far beyond the clinic.

The design of the study is deliberately straightforward. Half of the participants, all of whom will have alcohol use disorder, opioid use disorder, or both, will be randomly assigned to receive once-weekly semaglutide injections for 52 weeks. Crucially, the medication will be offered as an additional support layered on top of existing care, not as a replacement for traditional addiction treatment. Participants will remain eligible for all other behavioral health supports throughout the study period. Recruitment will focus on individuals who are clinically appropriate for GLP-1 medications and who face an elevated risk of criminal-justice involvement, a targeting strategy that reflects the county’s interest in directing new interventions toward those with the greatest needs and its broader commitment to reintegration and community safety.

The scientific rationale rests on a growing but still preliminary body of evidence. Phase 2 trials conducted internationally have indicated that GLP-1 receptor agonists can decrease heavy drinking among people with alcohol use disorder and reduce opioid craving among people with opioid use disorder. Prior research published in The Lancet and JAMA Psychiatry, along with earlier work on the related drug liraglutide, has suggested that these medications, originally developed to mimic gut hormones that regulate appetite and blood sugar, may also modulate reward circuitry in the brain. Researchers involved in the trial describe the effect in practical terms: rather than feeling dominated by cravings, whether for sugar, alcohol, or drugs, many patients report that GLP-1 medications help quiet that internal noise, restoring a sense of personal agency that addiction erodes.

What sets this trial apart from most addiction medication studies is the breadth of its outcome measures. Where typical trials primarily track substance use, this study will exploit Allegheny County’s nationally recognized linked administrative data infrastructure to examine whether treatment improves real-world outcomes across entire systems. Researchers will follow participants’ employment, housing stability, health care utilization and costs, mental health, self-control and impulsivity, weight, and involvement with the criminal justice system, including rearrest, reconviction, and reincarceration. The team will also calculate total fiscal and social costs, allowing the study to answer not only a clinical question but a policy one: whether any clinical benefit is large enough to justify sustained public investment.

The partnership behind the trial grew out of an unlikely collaboration between a research organization and a county government. Alex Jutca, Director of the Allegheny County Department of Human Services, described reaching out to CASPR executive director and co-founder Nicholas Reville two years ago after reading his addiction medicine blog. The two began talking regularly about GLP-1 medications, addiction, recidivism, and the challenges the county was facing, and the trial concept emerged from those conversations. The collaboration combines clinical treatment expertise, the county’s integrated data systems and social service partnerships, economic analysis, and addiction-policy expertise within a single randomized study, a structure its architects say is extremely unusual for county government.

Clinical leadership will come from UPMC Western Psychiatric Hospital’s Addiction Medicine Services, which will serve as the lead clinical site alongside other addiction treatment partners in Allegheny County. Antoine Douaihy, MD, Professor of Psychiatry and Medicine at the University of Pittsburgh School of Medicine and Senior Academic Director of Addiction Medicine Services at Western Psychiatric Hospital, said the trial examines the effectiveness and safety of GLP-1 receptor agonists and their impact on outcomes including employment, housing, health, and recidivism, noting that drug use disorders are major drivers of criminal justice involvement and intersect with systemic inequities and disparities. He expressed enthusiasm that the trial holds promise to change the landscape of addiction treatment and expand the recovery toolbox.

The research team itself is multidisciplinary by design, bringing together economists, addiction psychiatry specialists, and policy researchers from MIT, the University of Pittsburgh, the University of California San Diego, and UPMC Western Psychiatric Hospital. Named investigators include Diana Martínez Heredia of the Allegheny County Department of Human Services, Frank Schilbach and Dhruv Gaur of MIT, J. Travis Donahoe of the University of Pittsburgh, Gordon Dahl of the University of California San Diego, and Antoine Douaihy of UPMC. This composition allows the trial to be studied from clinical, economic, and behavioral angles simultaneously, an approach intended to produce evidence that can guide decisions well beyond Pittsburgh.

Indeed, scalability is a central theme of the trial’s design. Reville emphasized that because the intervention is a medication rather than a complex service program, a positive result in Pittsburgh should translate almost everywhere, making the trial easy for other cities to adopt. Jutca added that if results are positive, the county will consider the approach on an ongoing basis for individuals with substance use disorders and will work with other cities and counties across the country to disseminate findings, consistent with the broader goals of the Allegheny Recovery Partnership, which aims to build a coordinated system of care that keeps people engaged in treatment over time. Both leaders stressed that new medications become most valuable when integrated into systems that consistently support recovery.

The trial also builds on CASPR’s earlier pilot work, including a program with OpenDoors in Rhode Island that provides semaglutide to women in a post-incarceration sober housing program. Reville reported remarkable outcomes from that pilot, with women describing the disappearance of drug dreams and reporting that they felt better than they had ever felt, allowing them to rebuild careers and family relationships once cravings quieted. That program has drawn national media attention, including coverage in The New York Times and The Washington Post. Reville argued that GLP-1 medications may prove especially impactful because many patients are already familiar with the drug class and eager to take it, a level of patient enthusiasm he suggested could make a sustainable population-level impact possible and mark the most significant advancement in addiction medicine in decades.

Organizers are also attentive to the ethical dimensions of the work. Jutca said the team is working closely with community leaders and partners to ensure that trial participants are treated with respect throughout the process, noting that while addiction is widespread, its costs are unequally distributed. The county wants to demonstrate that widening inclusion in medical research is both important and possible while upholding high clinical and safety standards. CASPR, which funds and publishes research with the VA, created the first-ever pilot programs giving GLP-1 receptor agonists to patients receiving addiction treatment, and advocates for policies enabling faster medication development, is funded by individuals and foundations and accepts no direct or indirect funding from pharmaceutical companies. If the trial succeeds, its architects believe the result will be a major advance: a way to give people a better chance to recover, stay healthy, find employment, maintain stable housing, and avoid returning to the justice system.

Subject of Research: A randomized clinical trial testing whether semaglutide reduces alcohol and opioid use and justice involvement among adults with substance use disorders.

Article Title: CASPR and Allegheny County announce major new randomized clinical trial: GLP-1RA recovery and stability trial

Article References: CASPR and Allegheny County announce major new randomized clinical trial: GLP-1RA recovery and stability trial. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: semaglutide, GLP-1 receptor agonists, alcohol use disorder, opioid use disorder, randomized controlled trial, addiction medicine, recidivism, Allegheny County, CASPR, Arnold Ventures, criminal justice involvement, recovery